Chinese Chemosynthetic Polypeptide Drug Industry Analysed in New CRI Report Available at

19 Jul 2012 • by Natalie Aster

LONDON – In the pharmaceutical industry, chemosynthetic polypeptides are the focus of attentions. On one hand, the indications of polypeptide drugs are in wide range and the curative effects are obvious, mainly for the application of tumor, metabolism, cardiovascular diseases, infectious diseases, etc. On the other hand, the development-success ratio of polypeptide drugs is high compared to that of traditional drugs and the approval ratio is also obviously higher than that of micromolecule chemical drugs.

According to historical data, the approval ratio of polypeptide drugs in clinical research is 23 % to 26 %. As the rapid development of biochemical technologies and generic engineering field, polypeptide drugs are likely to replace the existing medicines.

New "Research Report on Chinese Chemosynthetic Polypeptide Drug Industry, 2012" worked out by China Research and Intelligence (CRI) offers a detailed and all-inclusive picture of the market by providing data and information on the following:

  • supply and demand of China's chemosynthetic polypeptide drugs; 
  • policy environment of China's chemosynthetic polypeptide drugs; 
  • China's major manufacturers of chemosynthetic polypeptide drugs; 
  • development trend of chemosynthetic polypeptide drugs.

Report Details:

Research Report on Chinese Chemosynthetic Polypeptide Drug Industry, 2012
Published: July, 2012
Pages: 60
Price: US$ 3.000,00

More new market research reports by the publisher can be found at China Research and Intelligence page.


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970